Research programme: exosome-based therapeutics - Codiak BioSciences

Drug Profile

Research programme: exosome-based therapeutics - Codiak BioSciences

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Codiak BioSciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Nov 2016 Codiak plans a phase I trial for Pancreatic cancer in USA (Codiac BioSciences website, November 2016)
  • 17 Nov 2015 Early research in Cancer in USA (unspecified route)
  • 17 Nov 2015 CodiaK Biosciences enters into a licensing and sponsored research agreement with University of Texas M. D. Anderson Cancer Center for exosome-based therapeutics and diagnostics (9207235; 9207236) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top